← All trials
NCT02990286
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2017
- Primary completion
- Jun 1, 2020
- Completion date
- Jan 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 122
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of ToulouseLead sponsor
- University of GrenobleOverall official - principal investigator
- University of Franche-ComtéOverall official - principal investigator
- University of StrasbourgOverall official - principal investigator
- University of NantesOverall official - principal investigator
- University of ParisOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- University of RennesOverall official - principal investigator
- University of LyonOverall official - principal investigator
- University of BurgundyOverall official - principal investigator
- University of ToulouseOverall official - principal investigator
- University of LorraineOverall official - principal investigator
- University of LilleOverall official - principal investigator
- François Rabelais UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.